
Credit ACIP/CDC
#19,345
One of the biggest challenges during any future H5Nx pandemic would be the rapid production and timely deployment of a two-dose (given 30 days apart) H5 vaccine to billions of people (see Referral: SCI AM - A Bird Flu Vaccine Might Come Too Late to Save Us from H5N1).
While it's not a new idea (see 2008's Seasonal Flu Vaccine May Offer Some Protection To H5N1), the notion of using the existing seasonal flu vaccine as either a `stop-gap measure' - or as a `prime-boost' for the first pandemic jab, during the opening months of an H5 pandemic - has persisted.
An early, encouraging 2010 study in the journal Vaccines (Seasonal influenza vaccine elicits heterosubtypic immunity against H5N1 that can be further boosted by H5N1 vaccination) reported:
Recent findings indicate that seasonal influenza vaccination or infection of healthy humans may contribute to heterosubtypic immunity against new influenza A subtypes, such as H5N1. Here, we investigated whether seasonal influenza vaccination in a mouse model could induce any immunity against the H5N1 subtype.
It could be demonstrated that, largely due to the H1N1 component strain A/NewCaledonia/20/99, parenteral immunization of mice with a trivalent seasonal influenza vaccine elicited heterosubtype H5-reactive antibodies able to confer partial protection against H5N1 influenza virus infection.
Furthermore, the trivalent seasonal influenza vaccine was found to be compatible with a whole virus H5N1 vaccine in a heterologous prime-boost immunization regimen, achieving superior efficacy compared to a single immunization with an equivalent low-dose of the H5N1 vaccine.
More recent evidence remains both mixed and modest - and has often relied on ferret or mouse models (which may not fully apply to humans) - including:
Nature Comms: Adjuvanted Influenza Vaccination Increases Pre-existing H5N1 Cross-reactive Antibodies
mBio: Low levels of influenza H5N1 HA and NA antibodies in the human population are boosted by seasonal H1N1 infection but not by H3N2 infection or influenza vaccination
EID Journal: Effect of Seasonal Influenza Vaccines on Avian Influenza A(H5N1) Clade 2.3.4.4b Virus Infection in Ferrets
EID Journal: Investigation of Influenza A(H5N1) Virus Neutralization by Quadrivalent Seasonal Vaccines, United Kingdom, 2021–2024
Note: Regardless of whether the seasonal flu vaccine directly protects against H5N1 infection, there are still good reasons to get the jab, prior to - and even during - an H5Nx pandemic.
- It still may provide some small boost to your immune response. Neutralizing antibodies aren't the only immune defense against infection.
- It could help prevent a co-infection with H5N1 and seasonal flu, which has the potential for being more severe.
- Co-infections could also help generate a reassorted `hybrid' virus (see Preprint: Intelligent Prediction & Biological Validation of the High Reassortment Potential of Avian H5N1 and Human H3N2 Influenza Viruses).
Limited added benefit of seasonal influenza vaccination before A(H5) vaccination in mice and ferrets challenged with A(H5N1)
Masato Hatta , Ying Huang , Jeremy A. Duke , Joseph R. Rouse , Chenchen Feng ,
Xudong Lin , show all
Article: 2731495 | Received 29 Jun 2026, Accepted 05 Sep 2026, Published online: 21 Sep 2026
https://doi.org/10.1080/22221751.2026.2731495
Limited A(H5)-specific vaccine supply is expected early in a potential A(H5N1) pandemic, raising the question of whether licensed seasonal influenza vaccines could enhance protection when administered before A(H5) vaccination. We evaluated this strategy in mouse and ferret models using clade 2.3.4.4b A(H5N1) viruses.
Seasonal influenza vaccination induced antibodies to seasonal haemagglutinins but did not induce detectable antibodies against A(H5) and did not consistently enhance A(H5)-directed antibody responses after A(H5) vaccination.
In lethal challenge studies, seasonal vaccine priming before A(H5) vaccination was associated with improved outcomes compared with A(H5) vaccination alone in one of three mouse experiments, but this effect was not observed in the other two mouse experiments or in ferrets. These findings suggest that seasonal influenza vaccine priming provides limited added benefit to A(H5) vaccine-mediated protection against A(H5N1) under the conditions tested.
(SNIP)Accordingly, clinical studies are needed to further evaluate the strategy of administering seasonal influenza vaccine prior to A(H5) vaccination. However, such studies would likely rely on immunological endpoints rather than direct assessment of protection. Evidence of cross-reactivity alone should therefore be interpreted cautiously when informing decision-making, as it may not reliably predict protection against severe or lethal A(H5N1) infection.
In the absence of a clear added benefit, prioritizing seasonal influenza vaccination as a priming strategy to enhance protection against A(H5N1) during the early phase of a pandemic may offer limited value, particularly when resources may need to be directed toward A(H5)-specific vaccination and other countermeasures. Continued efforts to improve the development, availability, and deployment of antigenically similar A(H5) vaccines should remain a priority for pandemic preparedness [13,14].
Although the prospect of using seasonal vaccine as a bridge - or as a primer for a first H5 dose - remains biologically plausible, the evidence of its effectiveness has been both inconsistent and weak.
Today's CDC study reports that prior seasonal vaccination offered little reproducible improvement over H5 vaccination alone (at least, in mice and ferrets). While disappointing, it is hardly unexpected.
Which suggests that during the opening months of any novel flu pandemic we will (once again) have to rely on NPIs (Non-pharmaceutical Interventions) like social distancing and face masks - and our limited supply of antivirals - while a strain-specific vaccine is produced and deployed.
For some specific preparedness advice, you may wish to revisit #Natlprep 2026: Pandemic Planning At Both Ends of the Spectrum.


